Adverse effects of thalidomide administration in patients with neoplastic diseases
- 1 October 2004
- journal article
- review article
- Published by Elsevier in The American Journal of Medicine
- Vol. 117 (7) , 508-515
- https://doi.org/10.1016/j.amjmed.2004.03.040
Abstract
No abstract availableKeywords
This publication has 83 references indexed in Scilit:
- Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple MyelomaJournal of Clinical Oncology, 2003
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapyBlood, 2002
- Thalidomide in Myelofibrosis with Myeloid Metaplasia: A Pooled-analysis of Individual Patient Data from Five StudiesLeukemia & Lymphoma, 2002
- Therapeutic dilemmas with thalidomide in multiple myeloma: Case discussionsSeminars in Oncology, 2001
- Thalomid?? (Thalidomide) CapsulesDrug Safety, 2001
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Exacerbation of acetaminophen hepatotoxicity by thalidomide and protection by nicotinic acid amideGeneral Pharmacology: The Vascular System, 1995
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Antithyroid Activity of N-Phthalyl Glutamic Acid Imide (K 17)BMJ, 1958